Suppr超能文献

[DLys(6)]-黄体生成素释放激素-姜黄素缀合物在体外和体内抑制胰腺癌细胞生长。

[DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo.

机构信息

William Hansel Cancer Prevention Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, USA.

出版信息

Int J Cancer. 2011 Oct 1;129(7):1611-23. doi: 10.1002/ijc.26132. Epub 2011 Jul 20.

Abstract

Pancreatic ductal adenocarcinomas are invariably lethal, and developing effective treatments that have minimal side effects is a challenge. Previous studies from our laboratory have shown that conjugates of cell membrane disrupting lytic peptides and luteinizing hormone releasing hormone (LHRH) target and destroy human prostate and breast cancer cells in xenografts in the nude mouse model (Hansel et al., Mol Cell Endocrinol 2007;260-262:183-9; Hansel et al., Mol Cell Endocrinol 2007;269:26-33), which express LHRH receptors. The objectives of our study were to synthesize a bioconjugate of LHRH analog ([DLys(6)]-LHRH) and a dietary microchemical (curcumin) and test the hypothesis that [DLys(6)]-LHRH-curcumin targets and inhibits pancreatic cancer cell growth in vitro and in vivo. In in vitro studies, we determined by confocal microscopy, flow cytometry analysis and reverse transcriptase-polymerase chain reaction that MIAPaCa-2, Panc-1 and BxPC-3 pancreatic cancer cell lines express LHRH receptors. [DLys(6)]-LHRH-curcumin inhibited cell proliferation of pancreatic cancer cell lines and induced apoptotic cell death (p < 0.05). Apoptosis was induced by cleavage of polyadenosine-5'-diphosphate-ribose-polymerase and caspase-3. The activity of [DLys(6)]-LHRH-curcumin was equal to free curcumin at equimolar concentrations in vitro. Unlike curcumin itself, the [DLys(6)]-LHRH-curcumin conjugate is water soluble which allows its intravenous administration. In two in vivo studies, [DLys(6)]-LHRH-curcumin given intravenously caused a significant (p < 0.01) reduction in tumor weights and volumes, and free curcumin given by gavage at an equal dose failed to cause a significant reduction in tumor weights and volumes in the nude mouse pancreatic cancer model. [DLys(6)]-LHRH-curcumin treatment enhanced apoptosis compared to [DLys(6)]-LHRH and vehicle-treated controls in tumor tissue. In conclusion, [DLys(6)]-LHRH-curcumin may be useful in treating pancreatic cancer.

摘要

胰腺导管腺癌总是致命的,开发具有最小副作用的有效治疗方法是一个挑战。我们实验室的先前研究表明,细胞膜破坏裂解肽和黄体生成素释放激素 (LHRH) 的缀合物靶向并破坏裸鼠模型中的异种移植物中的人前列腺癌和乳腺癌细胞 (Hansel 等人,Mol Cell Endocrinol 2007 ; 260-262:183-9; Hansel 等人,Mol Cell Endocrinol 2007 ; 269:26-33) ,它们表达 LHRH 受体。我们研究的目的是合成黄体生成素释放激素类似物 ([DLys(6)]-LHRH) 和膳食微量化学物质 (姜黄素) 的生物缀合物,并检验以下假设:[DLys(6)]-LHRH-姜黄素在体外和体内靶向并抑制胰腺癌细胞生长。在体外研究中,我们通过共聚焦显微镜、流式细胞术分析和逆转录-聚合酶链反应确定 MIAPaCa-2、Panc-1 和 BxPC-3 胰腺癌细胞系表达 LHRH 受体。[DLys(6)]-LHRH-姜黄素抑制胰腺癌细胞系的增殖并诱导细胞凋亡 (p < 0.05)。凋亡是通过多聚腺苷酸-5'-二磷酸核糖聚合酶和半胱天冬酶-3 的裂解诱导的。在体外,[DLys(6)]-LHRH-姜黄素的活性与等摩尔浓度的游离姜黄素相当。与姜黄素本身不同,[DLys(6)]-LHRH-姜黄素缀合物是水溶性的,允许其静脉给药。在两项体内研究中,静脉内给予[DLys(6)]-LHRH-姜黄素导致肿瘤重量和体积显著 (p < 0.01) 减少,而以相等剂量灌胃给予游离姜黄素未能导致裸鼠胰腺癌模型中肿瘤重量和体积的显著减少。与[DLys(6)]-LHRH 和载体处理的对照组相比,[DLys(6)]-LHRH-姜黄素处理增强了肿瘤组织中的细胞凋亡。总之,[DLys(6)]-LHRH-姜黄素可能对治疗胰腺癌有用。

相似文献

引用本文的文献

本文引用的文献

6
Peptide targeting of platinum anti-cancer drugs.肽靶向铂类抗癌药物。
Bioconjug Chem. 2009 Oct 21;20(10):1869-78. doi: 10.1021/bc900065r. Epub 2009 Sep 23.
7
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验